The findings of this meta-analysis support both the current NICE and ASCO guidelines that recommend considering or offering the use of NET to downstage ER-positive and HER2-negative tumours and increase local treatment options in postmenopausal women if there is no definite indication for chemotherapy10,11. The gene discussed is ERBB2; the disease is neoplasm.